Thus, robust syngeneic models that fully recapitulate the spontaneous spread of HER2+ve breast cancer to the brain and other organs would significantly improve our ability to evaluate the efficacy of targeted therapies against HER2+ve brain metastases. The gene discussed is ERBB2; the disease is breast cancer.